PRODUCTION OF ANTIBODIES AGAINST HER2 AND HER3 RECEPTORS IN BREAST CANCER TREATMENT AND THE SUPERIOR EFFECT OF THE SYNCHRONOUS BLOCKADE OF THESE RECEPTORS

被引:0
作者
Hedayatizadeh-Omran, A. [1 ,2 ]
Rafiei, A. [2 ,3 ]
Janbabaei, G. [1 ]
Ajami, A. [3 ]
Valadan, R. [2 ]
Alizadeh-Navaei, R. [1 ,2 ]
Tehrani, M. [2 ,3 ]
Omrani-Nava, V. [1 ]
Ahmadi, A. [4 ]
机构
[1] Mazandaran Univ Med Sci, Fac Med, Gastrointestinal Canc Res Ctr, Sari, Iran
[2] Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sari, Iran
[3] Mazandaran Univ Med Sci, Dept Immunol, Fac Med, Sari, Iran
[4] Mazandaran Univ Med Sci, Pharmaceut Sci Res Ctr, Fac Pharm, Sari, Iran
关键词
HER2; HER3; Antibody; Phage display;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The human epidermal growth factor receptor family (ErbB receptor family) plays an important role in the development of cancer. Antibody phage display technique is one of the powerful techniques that allows highly specific selection for antibody selection. Materials and Methods: In this study, by using antibody phage display technique, which is one of the powerful techniques for making antibodies in vitro, recombinant antibodies against ErbB2 and ErbB3 receptors were produced for inhibition of these receptors and compared the simultaneous blockage of these receptors with a synchronous block of HER2 and HER3. Results: We established a panel of stable cell lines expressing high levels of HER2 and HER3 and then we have produced antibodies with phage display technique against ErbB2 and ErbB3 receptors and compared the simultaneous blockage of these receptors with a synchronous block of HER2 and HER3. Conclusions: The specificity of antibodies obtained in this method was greatly improved and we've shown that synchronous block of HER2 and HER3 receptors has a superior effect compared with the monospecific block.
引用
收藏
页数:9
相关论文
共 28 条
  • [1] Monoclonal antibody therapy of cancer
    Adams, GP
    Weiner, LM
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (09) : 1147 - 1157
  • [2] ERBB receptors in cancer: signaling from the inside
    Arteaga, Carlos L.
    [J]. BREAST CANCER RESEARCH, 2011, 13 (02): : 304
  • [3] Beyond natural antibodies: the power of in vitro display technologies
    Bradbury, Andrew R. M.
    Sidhu, Sachdev
    Duebel, Stefan
    McCafferty, John
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (03) : 245 - 254
  • [4] Campion EM, 2011, METHODS MOL BIOL, V681, P229, DOI 10.1007/978-1-60761-913-0_13
  • [5] Identification and validation of cell surface antigens for antibody targeting in oncology
    Carter, P
    Smith, L
    Ryan, M
    [J]. ENDOCRINE-RELATED CANCER, 2004, 11 (04) : 659 - 687
  • [6] Selection of high-affinity phage antibodies from phage display libraries
    de Bruin, R
    Spelt, K
    Mol, J
    Koes, R
    Quattrocchio, F
    [J]. NATURE BIOTECHNOLOGY, 1999, 17 (04) : 397 - 399
  • [7] Antibody arrays for high-throughput screening of antibody-antigen interactions
    de Wildt, RMT
    Mundy, CR
    Gorick, BD
    Tomlinson, IM
    [J]. NATURE BIOTECHNOLOGY, 2000, 18 (09) : 989 - 994
  • [8] The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis
    Eceles, SA
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2001, 6 (04) : 393 - 406
  • [9] SV40-TRANSFORMED SIMIAN CELLS SUPPORT THE REPLICATION OF EARLY SV40 MUTANTS
    GLUZMAN, Y
    [J]. CELL, 1981, 23 (01) : 175 - 182
  • [10] ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
    GrausPorta, D
    Beerli, RR
    Daly, JM
    Hynes, NE
    [J]. EMBO JOURNAL, 1997, 16 (07) : 1647 - 1655